Incon

At a glance

Incon filed 52 disclosures in the last 12 months, including 5 insider, 3 5% holder, 2 issuance, 1 contract and 1 m&a. The most recent key filing was on Sep 4: Worth 11.6% of last year's revenue, over about 15 months.

Revenue for 2025 was ₩50.8B, up 3.5% on 2024. Operating margin was 3.3% against 3.3% a year earlier. Debt was 10% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩15.9B and operating loss of ₩1.1B.

The 2025 annual report lists 73 employees with an average tenure of 5.8 years and average pay of ₩52.4M, #1343 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩43.7M each on average. It paid no cash dividend for 2025. ㈜케이바이오컴퍼니 and related parties held 34.21% at year end.

From the 2025 annual report

Staff: 73 (51 men, 22 women), of whom 8 on fixed-term contracts. Total pay for the year: ₩3.8B. Directors and auditors: 5, paid ₩218.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜케이바이오컴퍼니 holds 34.21%; with 0 related parties the group holds 34.21% of common shares at year end.

Auditor: 우리회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 12% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary